Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy

Mol Ther. 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.

Abstract

Adoptive immunotherapy has emerged as a powerful approach to cure cancer and chronic infections. Currently, the generation of a massive number of T cells that provide long-lasting immunity is challenged by exhaustion and differentiation-associated senescence, which inevitably arise during in vitro cloning and expansion. To circumvent these problems, several studies have proposed an induced pluripotent stem cell (iPSC)-mediated rejuvenation strategy to revitalize the exhausted/senescent T cell clones. Because iPSC-derived cytotoxic T lymphocytes (iPSC-CTLs) generated via commonly used monolayer systems have unfavorable, innate-like features such as aberrant natural killer (NK) activity and limited replication potential, we modified the redifferentiation culture to generate CD8αβ+CD5+CCR7+CD45RA+CD56--adaptive iPSC-CTLs. The modified iPSC-CTLs exhibited early memory phenotype, including high replicative capacity and the ability to give rise to potent effector cells. In expansion culture with an optimized cytokine cocktail, iPSC-CTLs proliferated more than 1015-fold in a feeder-free condition. Our redifferentiation and expansion package of early memory iPSC-CTLs could supply memory and effector T cells for both autologous and allogeneic immunotherapies.

Keywords: T cell differentiation; iPS cell; rejuvenated T cell; stemness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism*
  • CD5 Antigens / metabolism
  • CD56 Antigen / deficiency
  • CD8 Antigens / metabolism
  • Cell Culture Techniques / methods*
  • Cell Differentiation
  • Cell Proliferation
  • Cells, Cultured
  • Cellular Reprogramming
  • Female
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Induced Pluripotent Stem Cells / cytology*
  • Induced Pluripotent Stem Cells / metabolism
  • K562 Cells
  • Leukocyte Common Antigens / metabolism
  • Mice
  • Neoplasms / therapy*
  • Receptors, CCR7 / metabolism
  • T-Lymphocytes, Cytotoxic / cytology*
  • T-Lymphocytes, Cytotoxic / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Biomarkers
  • CCR7 protein, human
  • CD5 Antigens
  • CD56 Antigen
  • CD8 Antigens
  • CD8alphabeta antigen
  • NCAM1 protein, human
  • Receptors, CCR7
  • Leukocyte Common Antigens